Breye Therapeutics is a clinical-stage biopharmaceutical company based in Copenhagen, Denmark, developing novel oral small-molecule therapies for retinal vascular diseases. The company is focused on de-risked small molecules suited for oral administration with a scientific rationale for treating diabetic retinopathy and age-related macular degeneration. Breye intends to use the new funding to expand its team and broaden its pipeline across a wider range of ophthalmologic diseases. The company is led by CEO Ulrik Mouritzen and is part of Novo Seeds’ company-creation efforts, with involvement from Novo Holdings’ early-stage investment team. Pre-seed support for Breye included funding from the BioInnovation Institute (BII), the Danish Growth Foundation (Vækstfonden) and the Danish Innovation Foundation (Innovationsfonden).

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2022